D
David M. Waterhouse
Researcher at Sarah Cannon Research Institute
Publications - 112
Citations - 12010
David M. Waterhouse is an academic researcher from Sarah Cannon Research Institute. The author has contributed to research in topics: Nivolumab & Bevacizumab. The author has an hindex of 29, co-authored 99 publications receiving 9687 citations. Previous affiliations of David M. Waterhouse include University of Michigan.
Papers
More filters
Journal ArticleDOI
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
Julie R. Brahmer,Karen L. Reckamp,Paul Baas,Lucio Crinò,Wilfried Eberhardt,Elena Poddubskaya,Scott J. Antonia,Adam Pluzanski,Everett E. Vokes,Esther Holgado,David M. Waterhouse,Neal Ready,Justin F. Gainor,Osvaldo Arén Frontera,Libor Havel,Martin Steins,Marina Chiara Garassino,Joachim G.J.V. Aerts,Manuel Domine,Luis Paz-Ares,Martin Reck,Christine Baudelet,Christopher T. Harbison,Brian Lestini,David R. Spigel +24 more
TL;DR: Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab than with docetaxel, regardless of PD-L1 expression level.
Journal ArticleDOI
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).
Leora Horn,David R. Spigel,Everett E. Vokes,Esther Holgado,Neal Ready,Martin Steins,Elena Poddubskaya,Hossein Borghaei,Enriqueta Felip,Luis Paz-Ares,Adam Pluzanski,Karen L. Reckamp,Marco Angelo Burgio,Martin Kohlhaeufl,David M. Waterhouse,Fabrice Barlesi,Scott J. Antonia,Oscar Arrieta,Jérôme Fayette,Lucio Crinò,Naiyer A. Rizvi,Martin Reck,Matthew D. Hellmann,William J. Geese,Ang Li,Anne Blackwood-Chirchir,Diane Healey,Julie R. Brahmer,Wilfried Eberhardt +28 more
TL;DR: Nivolumab provides long-term clinical benefit and a favorable tolerability profile compared with docetaxel in previously treated patients with advanced NSCLC and is reported on in a pooled analysis of the two studies.
Journal ArticleDOI
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
Everett E. Vokes,Neal Ready,Enriqueta Felip,Leora Horn,Marco Angelo Burgio,S.J. Antonia,O. Aren Frontera,Scott N. Gettinger,Esther Holgado,David R. Spigel,David M. Waterhouse,Manuel Domine,Marina Chiara Garassino,Laura Q.M. Chow,George R. Blumenschein,Fabrice Barlesi,Bruno Coudert,Justin F. Gainor,Oscar Arrieta,Julie R. Brahmer,Charles Butts,Martin Steins,William J. Geese,Ang Li,Diane Healey,L. Crinò +25 more
TL;DR: In this article, the anti-programmed death-1 antibody nivolumab versus docetaxel was compared in patients with previously treated advanced squamous (CheckMate 017) and nonsquamous NSCLC.
Journal ArticleDOI
Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring.
TL;DR: Microelectronic adherence monitoring provides both confirmatory and complimentary data regarding adherence behavior, while also allowing for the evaluation of patterns of nonadherence.
Journal ArticleDOI
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.
Tomasz M. Beer,Christopher W. Ryan,Peter Venner,Daniel P. Petrylak,Gurkamal Chatta,J. Dean Ruether,Charles H. Redfern,Louis Fehrenbacher,Mansoor N. Saleh,David M. Waterhouse,Michael A. Carducci,Daniel Vicario,Robert Dreicer,Celestia S. Higano,Frederick R. Ahmann,Kim N. Chi,W. David Henner,Alan Arroyo,Fong Clow +18 more
TL;DR: DN-101 treatment was associated with improved survival, but this will require confirmation because survival was not a primary end point, and the addition of weekly DN-101 did not increase the toxicity of weekly docetaxel.